Semaglutide vs. Tirzepatide: How the GLP-1 Options Differ

Semaglutide and tirzepatide are the two prescription medications most often mentioned in conversations about medical weight loss. Both require a prescription and medical supervision, but they work through different mechanisms.

What they have in common

Both are injectable, both began as type 2 diabetes treatments, and both are now studied and approved for weight management. They slow gastric emptying, reduce appetite, and improve insulin sensitivity, administered weekly via subcutaneous injection.

The shared foundation is GLP-1 — glucagon-like peptide-1, a gut hormone that signals fullness and regulates blood sugar.

The core difference: one pathway vs. two

Semaglutide is a GLP-1 receptor agonist — it activates the GLP-1 receptor and nothing else.

Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). By engaging two pathways, tirzepatide appears to produce stronger effects on both weight and glycemic control in head-to-head comparisons.

What the trials show

In trials, semaglutide at the higher weight-management dose produced average weight loss in the mid-teens percent of body weight over roughly a year. Tirzepatide showed dose-dependent outcomes, with the highest studied dose producing larger average losses.

Direct comparisons have generally favored tirzepatide for both weight loss and A1C reduction — but these are population averages, not guarantees for any individual.

Side effects and tolerability

Both share a similar side effect profile, primarily gastrointestinal: nausea, diarrhea, constipation, vomiting, especially during dose escalation. Most people adapt over time. Both carry warnings about thyroid C-cell tumors (from rodent studies), pancreatitis, and gallbladder issues. Neither should be used during pregnancy.

Practical considerations

Both are expensive without insurance and availability has fluctuated. Semaglutide has a longer track record; tirzepatide is newer. Dosing for both starts low and titrates up over weeks.

There's no simple rule for who should use which. People who don't respond adequately to one sometimes do better on the other. The choice depends on individual response, tolerance, history, cost, and access.

The bottom line

Tirzepatide's dual-receptor approach produces numerically greater weight loss on average; semaglutide remains highly effective with a longer track record. Both require medical supervision and work best alongside sustainable changes to eating and movement.